| Title |
LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD
|
|---|---|
| Published in |
International Journal of Chronic Obstructive Pulmonary Disease, June 2015
|
| DOI | 10.2147/copd.s84436 |
| Pubmed ID | |
| Authors |
Santanu Sannigrahi, Changzheng Wang, Xiangdong Zhou, Nuofu Zhang, Michael Humphries, Linda Wang, Chau Thach, Francesco Patalano, Donald Banerji, Nanshan S Zhong |
| Abstract |
The current Global initiative for chronic Obstructive Lung Disease (GOLD) treatment strategy recommends the use of one or more bronchodilators according to the patient's airflow limitation, their history of exacerbations, and symptoms. The LANTERN study evaluated the effect of the long-acting β2-agonist (LABA)/long-acting muscarinic antagonist (LAMA) dual bronchodilator, QVA149 (indacaterol/glycopyrronium), as compared with the LABA/inhaled corticosteroid, salmeterol/fluticasone (SFC), in patients with moderate-to-severe COPD with a history of ≤1 exacerbation in the previous year. In this double-blind, double-dummy, parallel-group study, 744 patients with moderate-to-severe COPD with a history of ≤1 exacerbations in the previous year were randomized (1:1) to QVA149 110/50 μg once daily or SFC 50/500 μg twice daily for 26 weeks. The primary endpoint was noninferiority of QVA149 versus SFC for trough forced expiratory volume in 1 second (FEV1) at week 26. Overall, 676 patients completed the study. The primary objective of noninferiority between QVA149 and SFC in trough FEV1 at week 26 was met. QVA149 demonstrated statistically significant superiority to SFC for trough FEV1 (treatment difference [Δ]=75 mL; P<0.001). QVA149 demonstrated a statistically significant improvement in standardized area under the curve (AUC) from 0 hours to 4 hours for FEV1 (FEV1 AUC0-4h) at week 26 versus SFC (Δ=122 mL; P<0.001). QVA149 and SFC had similar improvements in transition dyspnea index focal score, St George Respiratory Questionnaire total score, and rescue medication use. However, QVA149 significantly reduced the rate of moderate or severe exacerbations by 31% (P=0.048) over SFC. Overall, the incidence of adverse events was comparable between QVA149 (40.1%) and SFC (47.4%). The incidence of pneumonia was threefold lower with QVA149 (0.8%) versus SFC (2.7%). These findings support the use of the LABA/LAMA, QVA149 as an alternative treatment, over LABA/inhaled corticosteroid, in the management of moderate-to-severe COPD patients (GOLD B and GOLD D) with a history of ≤1 exacerbation in the previous year. |
X Demographics
The data shown below were collected from the profiles of 34 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 3 | 9% |
| Switzerland | 2 | 6% |
| United States | 2 | 6% |
| India | 1 | 3% |
| Canada | 1 | 3% |
| Japan | 1 | 3% |
| Kenya | 1 | 3% |
| France | 1 | 3% |
| Spain | 1 | 3% |
| Other | 1 | 3% |
| Unknown | 20 | 59% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 29 | 85% |
| Practitioners (doctors, other healthcare professionals) | 4 | 12% |
| Science communicators (journalists, bloggers, editors) | 1 | 3% |
Mendeley readers
The data shown below were compiled from readership statistics for 133 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 2 | 2% |
| Spain | 1 | <1% |
| Sweden | 1 | <1% |
| Austria | 1 | <1% |
| Unknown | 128 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 17 | 13% |
| Student > Master | 15 | 11% |
| Other | 14 | 11% |
| Researcher | 14 | 11% |
| Student > Postgraduate | 14 | 11% |
| Other | 30 | 23% |
| Unknown | 29 | 22% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 53 | 40% |
| Pharmacology, Toxicology and Pharmaceutical Science | 13 | 10% |
| Nursing and Health Professions | 11 | 8% |
| Biochemistry, Genetics and Molecular Biology | 6 | 5% |
| Agricultural and Biological Sciences | 6 | 5% |
| Other | 11 | 8% |
| Unknown | 33 | 25% |
Attention Score in Context
This research output has an Altmetric Attention Score of 40. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 22 October 2019.
All research outputs
#1,026,761
of 25,371,288 outputs
Outputs from International Journal of Chronic Obstructive Pulmonary Disease
#42
of 2,577 outputs
Outputs of similar age
#12,325
of 281,399 outputs
Outputs of similar age from International Journal of Chronic Obstructive Pulmonary Disease
#1
of 71 outputs
Altmetric has tracked 25,371,288 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 95th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,577 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.5. This one has done particularly well, scoring higher than 98% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 281,399 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 95% of its contemporaries.
We're also able to compare this research output to 71 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 98% of its contemporaries.